

Correction to Enhanced Sensitivity Employing Zwitterionic and pI Balancing Dyes (Z-CyDyes) Optimized for 2D-Gel Electrophoresis Based on Side Chain Modifications of CyDye Fluorophores. New Tools For Use in Proteomics and Diagnostics

Mark G. Epstein, Benjamin D. Reeves, Walid S. Maaty, David Fouchard, Edward A. Dratz, Brian Bothner, and Paul A. Grieco*

Bioconjugate Chemistry 2013, 24, 1552–1561. DOI: 10.1021/bc4002213

Compound 10, Page 1554, column 2, Paragraph 1, line 19:

“(2R)-3-((2-((5-Carboxypentyl)(methyl)ammonio)ethyl)-amino)-2-(2-(4-((2-((1E,3Z)-3-(3-ethylbenzo[d]oxazol-2(3H)-ylidene)prop-1-en-1-yl)benzo[d]oxazol-3-ium-3-yl)-methyl)phenyl)acetamido)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”

needs to be changed to:

“(2R)-3-((2-((5-carboxypentyl)(methyl)ammonio)ethyl)-amino)-2-(2-(4-(((E)-2-((E)-3-(3-ethylbenzo[d]oxazol-3-ium-2-yl)allylidene)benzo[d]oxazol-3(2H)-yl)methyl)phenyl)-acetamido)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”.

Compound 1, Page 1154, column 2, paragraph 2, line 49:

“(2R)-3-((2-((6-((2,5-Dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)(methyl)ammonio)ethyl)amino)-2-(2-(4-((2-((1E,3Z)-3-(3-ethylbenzo[d]oxazol-2(3H)-ylidene)prop-1-en-1-yl)benzo[d]oxazol-3-ium-3-yl)methyl)phenyl)-acetamido)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”

needs to be changed to:

“(2R)-3-((2-((6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)(methyl)ammonio)ethyl)amino)-2-(2-(4-(((E)-2-((E)-3-(3-ethylbenzo[d]oxazol-3-ium-2-yl)allylidene)benzo[d]oxazol-3(2H)-yl)methyl)phenyl)-acetamido)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”.

Compound 11, Page 1555, column 1, paragraph 1, line 17:

“(2R)-3-((2-((5-Carboxypentyl)(methyl)ammonio)-ethyl)-amino)-2-(6-(2-((E)-3-((E)-3,3-dimethyl-1-propylindolin-2-ylidene)prop-1-en-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)-hexanamido)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”

needs to be changed to:

“(2R)-3-((2-((5-carboxypentyl)(methyl)ammonio)ethyl)-amino)-2-(6-((Z)-2-((E)-3-(3,3-dimethyl-1-propyl-3H-indol-1-ium-2-yl)allylidene)-3,3-dimethylindolin-1-yl)hexanamido)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”.

Compound 2, Page 1555, column 1, paragraph 2, line 47:

“(2R)-2-(6-(2-((E)-3-((E)-3,3-dimethyl-1-propylindolin-2-ylidene)prop-1-en-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)-hexanamido)-3-((2-((6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)(methyl)ammonio)ethyl)amino)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”

needs to be changed to:

“(2R)-2-(6-((Z)-2-((E)-3-(3,3-dimethyl-1-propyl-3H-indol-1-ium-2-yl)allylidene)-3,3-dimethylindolin-1-yl)hexanamido)-3-((2-((6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-methyl)ammonio)ethyl)amino)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”.

Compound 12, Page 1555, column 2, paragraph 1, line 15:

“(2R)-3-((2-((5-carboxypentyl)(methyl)ammonio)ethyl)-amino)-2-(6-(3,3-dimethyl-2-((1E,3E)-5-((E)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium-1-yl)-hexanamido)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”

needs to be changed to:

“(2R)-3-((2-((5-carboxypentyl)(methyl)ammonio)ethyl)-amino)-2-(6-((Z)-3,3-dimethyl-2-((2E,4E)-5-(1,3,3-trimethyl-3H-indol-1-ium-2-yl)penta-2,4-dien-1-ylidene)indolin-1-yl)-hexanamido)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”.

Compound 3, Page 1555, column 2, paragraph 2, line 47:

“(2R)-2-(6-(3,3-dimethyl-2-((1E,3E)-5-((E)-1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-indol-1-ium-1-yl)-hexanamido)-3-((2-((6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)(methyl)ammonio)ethyl)amino)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”

needs to be changed to:

“(2R)-2-(6-((Z)-3,3-dimethyl-2-((2E,4E)-5-(1,3,3-trimethyl-3H-indol-1-ium-2-yl)penta-2,4-dien-1-ylidene)indolin-1-yl)-hexanamido)-3-((2-((6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)(methyl)ammonio)ethyl)amino)-3-oxopropane-1-sulfonate 2,2,2-trifluoroacetate”.

Compound 13, Page 1556, column 1, paragraph 1, line 15:

“5-((E)” needs to be changed to: “5-((Z)”.

Published: March 14, 2014

